Fast Five Quiz: Management of Obesity

Elif A. Oral, MD; Evelyn S. Marienberg, MD


December 19, 2022

Pharmacotherapy can be considered as an adjunct to comprehensive lifestyle management for certain individuals who meet the agent's label indications. Guidelines suggest that antiobesity drug therapy be considered for individuals with a BMI ≥ 27 with comorbidity or for those with BMI > 30 without comorbidity, and those who have not achieved weight loss goals (≥ 5% of total body weight in 3-6 months) after implementing comprehensive lifestyle intervention. According to the American College of Cardiology and American Heart Association Task Force, metabolic surgery can be considered for motivated individuals with a BMI ≥ 35 with comorbidity or BMI ≥ 40 with no comorbidity, again as an adjunct to lifestyle management.

Neither antiobesity drug therapy nor drug therapy of comorbidities should be used alone, without lifestyle interventions per Hamdy and colleagues.

Learn more about approaches to the management of obesity.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.